Latest news

• FDA questions safety profile of AZ, FibroGen’s anaemia drug roxadustat

  According to this analysis, roxadustat was comparable to epoetin alfa, a standard therapy for anaemia in CKD, on the composite measure of major adverse cardiovascular events (MACE). ... events. The risk is thought to be most acute with epoetin alfa when

• GSK files anaemia drug daprodustat in Japan, its first market

  If approved, daprodustat would be an oral alternative to erythropoiesis-stimulating agents (ESAs) such as Kyowa Kirin’s Espo (epoetin alfa) and biosimilars that have to be delivered by injection.

• AZ preps new roxadustat filings, though data foxes investors

  events. The risk is thought to be most acute with epoetin alfa when treatment is started, typically in patients in newly-initiated (incident) dialysis. ... Epoetin alfa is sold by Amgen as Epogen and Janssen as Procrit, but these brands were joined by

• First-line ovarian approval cements AZ’s Lynparza lead

  The ROCKIES trial revealed a significant improvement for the oral drug in haemoglobin versus injectable epoetin alfa in dialysis-dependent CKD patients, the patient population for which it has just been

• China first market to approve AZ’s kidney drug roxadustat

  as Amgen’s Epogen (epoetin alfa) and Aranesp (darbepoetin alfa). ... Roxadustat was compared to treatment with epoetin alfa over 26 weeks, matching the ESA’s efficacy in achieving a significant increase in haemoglobin levels.